Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biogen, Inc. (NQ: BIIB )

326.73 USD -2.44 (-0.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Stories about Biogen, Inc.

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Will Biogen Be Able to Move Past the Drama Surrounding Its Alzheimer's Disease Drug?
Probably. 
Tags BIIB Market News
From Motley Fool
Biogen: Does Aduhelm Make it the Next Dendreon?
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aduhelm was approved by the FDA, priced at $56,000/year, but it isn't a cure for Alzheimer's. The post Biogen: Does Aduhelm Make it the... 
Tags Market News LLY BMY
From InvestorPlace
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags DXCM TBIO Guidance
From Benzinga
Is Now a Good Time to Buy Biogen Stock?
It's a definite maybe. 
Tags BIIB Market News
From Motley Fool
Why Biogen's Stock Has Likely Peaked
The stock has a tough road back to $400, assuming it can get back there at all. 
Tags LLY BIIB Market News
From Motley Fool
Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday
A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business. 
Tags SAVA AVXL Market News
From Motley Fool
Annovis Bio Shares Cut In Half Following Alzheimer's Data Presentation
Annovis Bio, Inc. (NYSE: ANVS), which took off on a strong rally in January, has quickly lost most of the gains. What To Know: ... 
Tags Biotech Small Cap Movers
From Benzinga
Should You Invest in This Seemingly Unstoppable Alzheimer's Biotech?
This popular life science company has a fair but risky shot of developing a novel drug to treat Alzheimer's disease. 
Tags BIIB SAVA Market News
From Motley Fool
This Under-the-Radar Dementia Treatment Could Reward Investors
Want to dabble in the market for Alzheimer's therapies but avoid Biogen? Look no further. 
Tags Market News BTAI BIIB
From Motley Fool
What's Next for FibroGen After an FDA Vote Against Its Anemia Drug?
FDA approval of roxadustat seems unlikely. 
Tags AMGN AZN BIIB
From Motley Fool
Top Biotech Stocks To Watch After Bristol Myers’ Opdivo Sees Q2 Growth
Tags Market News
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
3 Diverse Forever Tech Stocks to Buy Today
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Out-of-favor discounting has led to the intersection of value and growth on the price charts of three industry-leading tech stocks. The... 
Tags Trading Advice NEE Market News
From InvestorPlace
After Aduhelm Win, Biogen Touts Encouraging Data From Second Alzheimer's Candidate
Biogen Inc(NASDAQ: BIIB) andIonis Pharmaceuticals Inc(NASDAQ: IONS)have announced topline datafrom a ... 
Tags General BIIB Benzinga
From Benzinga
Analysis Shows Biogen-Eisai's Aduhelm Slows Cognitive, Functional Decline In Early Alzheimer's Patients
An analysis of Phase 3 data presented byBiogen Inc(NASDAQ: BIIB) andEisai Co Ltd(OTC: ESALY) of its ... 
Tags News Aduhelm Alzheimer's disease
From Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs, And More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefited from the optimism that was set in motion by the solid start to the pharma reporting... 
Tags Healthcare Pharma/Biotech Stocks / Equities
From Blogs - TalkMarkets
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism ... 
Tags ALEC Penny Stocks OPK
From Benzinga
Could These 3 Potential Blockbusters Transform Biogen?
The company is moving into three billion-dollar areas. 
Tags BIIB SAGE Market News
From Motley Fool
Notable Friday Option Activity: SPLK, CWH, BIIB
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Splunk Inc (SPLK), where a total of 9,728 contracts have traded so far, representing... 
Tags Stocks
From Market News Video
Expert Ratings For Biogen
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months ... 
Tags Market News BZI/AAR Analyst Ratings
From Benzinga
Investors Too Gloomy Over Biogen Alzheimer’s Drug
There are good reasons to be skeptical that Biogen’s Aduhelm, the first new treatment for Alzheimer’s disease in nearly two decades, will change patients’ lives for the better. 
Tags Stocks / Equities Market News Pharma/Biotech
From Blogs - TalkMarkets
Stocks Showing Improved Relative Strength: Biogen
Biogen shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
From Investor's Business Daily
Biogen inc (BIIB) Q2 2021 Earnings Call Transcript
BIIB earnings call for the period ending June 30, 2021. 
Tags Market News BIIB
From Motley Fool
Cassava Sciences Stock Soars In Anticipation Of Alzheimer's Data: A Technical Analysis
On Thursday,Cassava Sciences, Inc (NASDAQ: SAVA) smashed through a resistance levelat $117.54, made 21 years ago between its ... 
Tags Technicals News Long Ideas
From Benzinga
Biogen, under pressure, tells investors it ‘stands by’ the FDA review process for its Alzheimer’s drug
Biogen executives sought to assure investors that the science behind its newly approved Alzheimer’s disease drug is firm despite ongoing questions about whether the drug works, how it was approved, and... 
Tags SPX BIIB
From MarketWatch
IGC Stock: The Huge Cannabis Patent News That Has IGC Flying High
InvestorPlace - Stock Market News, Stock Advice & Trading Tips IGC stock is moving up in a huge way today. The company is finally earning its patent for the treatment of Alzheimer's disease with... 
Tags IGC NYSE:IGC,NASDAQ:BIIB,NASDAQ:SAVA SAVA
From InvestorPlace
Biogen's Q2 Profit Falls 70% As Tecfidera Competition Hits Topline
Biogen Inc posted Q2 adjusted EPS of $5.68 ahead of the consensus estimate of $4.55, but quarterly profit fell around 71% Y/Y to $448.5 million as competition intensified for the Company's flagship... 
Tags Pharma/Biotech Market News Stocks / Equities
From Blogs - TalkMarkets
The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ... 
Tags HCWB SAVA MCRB
From Benzinga
Biogen: Q2 Earnings Insights
Shares of Biogen (NASDAQ:BIIB) fell 0.3% in pre-market trading after the company reported Q2 results. Quarterly ... 
Tags Earnings Benzinga BIIB
From Benzinga
Biogen's Q2 Profit Falls 70% As Tecfidera Competition Hits Topline
Biogen Inc(NASDAQ: BIIB)posted Q2 adjusted EPSof $5.68 ahead of the consensus estimate of $4.55, but quarterly profit ... 
Tags Briefs Market News Earnings
From Benzinga
Biogen Earnings, Sales Top Q2 Views; Stock Rises
Biogen earnings and sales fell, but beat second-quarter forecasts. Biogen stock rose slightly before Thursday's open. 
From Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.